Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced the promotion of Thomas Englese to chief commercial officer, effective immediately. Englese, who previously served as executive vice president of commercial operations since September 2024, will continue to oversee sales, marketing, market access, and commercial operations for TONMYA, the company's treatment for fibromyalgia in adults, as well as Zembrace(R) SymTouch(R) and Tosymra(R) for acute migraine in adults.
This promotion comes at a pivotal time for Tonix as it works to maximize the potential of TONMYA, which was approved by the U.S. Food and Drug Administration and is the first new treatment for fibromyalgia in more than 15 years. The company is focused on expanding patient access and growing its prescriber base, with an emphasis on increasing sales as it broadens the TONMYA launch. Seth Lederman, president and CEO of Tonix, noted that Englese has been instrumental in building the company's commercial organization and launching TONMYA, underscoring the importance of this leadership role in driving the company's commercial strategy.
Englese's extensive experience in the pharmaceutical industry positions him well to lead these efforts. In his expanded role, he will be responsible for directing all commercial activities, including brand strategy, field sales, marketing, and market access. His leadership is expected to be crucial as Tonix continues to establish TONMYA in the fibromyalgia market and supports its migraine products.
The announcement highlights Tonix's commitment to addressing high unmet medical needs in the central nervous system (CNS) and immunology therapeutic areas. Beyond its commercial portfolio, Tonix is advancing a robust pipeline of product candidates. The company is currently conducting Phase 2 clinical trials to evaluate TONMYA's potential in major depressive disorder and acute stress disorder. Additionally, its CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In the immunology space, Tonix is developing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
With this promotion, Tonix is signaling its strategic focus on commercial execution and growth. The company's ability to successfully market TONMYA will be a key driver of its near-term performance, and Englese's leadership will be instrumental in achieving that goal. Investors and stakeholders will be watching closely as Tonix expands its commercial footprint and advances its pipeline.
For more information about Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP. The full press release can be viewed at https://ibn.fm/uzRyl.
